BMO Capital analyst Etzer Darout raised the firm’s price target on BioNTech (BNTX) to $143 from $130 and keeps an Outperform rating on the shares after its FY24 results. The firm continues to view the COVID business as supportive of the company’s focus shift to Oncology and expects its clinical and regulatory updates over the next 12-18 months to reinforce its view and drive share upside, the analyst tells investors in a research note. BMO is also positive on the company’s ability to deploy significant capital for business development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s 2024 Earnings Highlight Oncology Focus
- Cautious Outlook for BioNTech SE Amid Revenue Shortfall and Oncology Pipeline Uncertainty
- BioNTech price target lowered to $143 from $147 at BofA
- BNTX Earnings: BioNTech Stock Slips Despite Q4 Beats
- Morning Movers: Redfin soars and Rocket Companies dips following deal
Questions or Comments about the article? Write to editor@tipranks.com